Strain-specific differences in the development of neuronal excitability in the mouse ventral nucleus of the trapezoid body.
Strain-specific differences in the development of neuronal excitability in the mouse ventral nucleus of the trapezoid body. Hear Res. 2017 Aug 18;354:28-37 Authors: Sinclair JL, Barnes-Davies M, Kopp-Scheinpflug C, Forsythe ID Abstract This investigation compared the development of neuronal excitability in the ventral nucleus of the trapezoid body (VNTB) between two strains of mice with differing progression rates for age-related hearing loss. In contrast to CBA/Ca (CBA) mice, the C57BL/6J (C57) strain are subject to hearing loss from a younger age and are more prone to damage from sound over-exposure. Higher firing rates in the medial olivocochlear system (MOC) are associated with protection from loud sounds and these cells are located in the VNTB. We postulated that reduced neuronal firing of the MOC in C57 mice could contribute to hearing loss in this strain by reducing efferent protection. Whole cell patch clamp was used to compare the electrical properties of VNTB neurons from the two strains initially in two age groups: before and after hearing onset at ∼ P9 and ∼P16, respectively. Prior to hearing onset VNTB neurons electrophysiological properties were identical in both strains, but started to diverge after hearing onset. One week after hearing onset VNTB neurons of C57 mice had larger amplitude action potentials but in contrast to CBA mice, their waveform failed to accelerate with increasing age, consistent with the faster inact...
Authors: Fischetti A, Romano N, Mussetto I, Merlo G, Burlando M, Cozzani E, Muda A, Garlaschi G, Parodi A PMID: 30229643 [PubMed - as supplied by publisher]
Authors: Brambilla L, Minuti A, Brambilla M, Tourlaki A, Genovese G, Berti E PMID: 30229642 [PubMed - as supplied by publisher]
Authors: Veraldi S, Moltrasio C, Spinelli F, Nazzaro G PMID: 30229641 [PubMed - as supplied by publisher]
Authors: Radi G, Campanati A, Diotallevi F, Molinelli E, Offidani A Abstract BACKGROUND: Apremilast is a "small molecule", an oral phosphodiesterase 4 inhibitor indicated for the twice- daily treatment of adults with psoriasis (PsO) and psoriatic arthritis (PsA). Data concerning clinical experience in real world setting with Apremilast for psoriasis are still exiguous, and aim of this report is to provide our experience in the use of Apremilast in out-patient setting. METHODS: Ten caucasian individuals (6 male, 4 females; mean age 69,3; range 53-81 years) affected by moderate to severe plaque psoriasi...
Authors: Di Prete M, Ferlosio A, Mazzilli S, Bianchi L, Orlandi A, Campione E PMID: 30229639 [PubMed - as supplied by publisher]
Authors: Rossi A, Garelli V, Muscianese M, Pranteda G, Caro G, D'arino A, Fortuna MC PMID: 30229638 [PubMed - as supplied by publisher]
Authors: Gualtieri B, Panduri S, Chiricozzi A, Romanelli M PMID: 30229637 [PubMed - as supplied by publisher]
CONCLUSIONS: This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regular cutaneous follow up for this subset of patients. PMID: 30229636 [PubMed - as supplied by publisher]
Authors: Caposiena Caro RD, Coppola A, Didona D PMID: 30229635 [PubMed - as supplied by publisher]
CONCLUSIONS: This study suggests that topical EGF is a safe, noninvasive, and effective treatment for melasma. J Drugs Dermatol. 2018;17(6):970-973. PMID: 30235384 [PubMed - in process]